STAT+: Two drug makers, two commercial launches — with divergent results
Biocryst Pharma did it. Aurinia Pharma did not.
The “it” is a successful, commercial drug launch. Biocryst reported a better-than-expected $10.9 million in sales for its drug Orladeyo in the March quarter — the first public assessment of the medicine’s marketing progress since it was approved last December.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Two drug makers, two commercial launches — with divergent results »
